These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26694654)

  • 61. Health technology assessment and primary data collection for reducing uncertainty in decision making.
    Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
    J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?
    ; Neumann PJ; Drummond MF; Jönsson B; Luce BR; Schwartz JS; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2010 Jan; 26(1):71-8. PubMed ID: 20059783
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Technological developments and approaches to improving service quality.
    Blumberg MR
    Biomed Instrum Technol; 1999; 33(1):35-44. PubMed ID: 10067179
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Multi-criteria decision analysis for health technology resource allocation and assessment: so far and so near?].
    Campolina AG; Soárez PC; Amaral FVD; Abe JM
    Cad Saude Publica; 2017 Oct; 33(10):e00045517. PubMed ID: 29091169
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices.
    Elshaug AG; Hiller JE; Tunis SR; Moss JR
    Aust New Zealand Health Policy; 2007 Oct; 4():23. PubMed ID: 17973993
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience.
    Levin L; Goeree R; Sikich N; Jorgensen B; Brouwers MC; Easty T; Zahn C
    Int J Technol Assess Health Care; 2007; 23(3):299-309. PubMed ID: 17579931
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications.
    Maloney MA; Schwartz L; O'Reilly D; Levine M
    Int J Technol Assess Health Care; 2019; 35(5):384-392. PubMed ID: 31524113
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [A good lesson.].
    Demicheli V
    Recenti Prog Med; 2019 Dec; 110(12):561-562. PubMed ID: 31909758
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A novel research design can aid disinvestment from existing health technologies with uncertain effectiveness, cost-effectiveness, and/or safety.
    Haines T; O'Brien L; McDermott F; Markham D; Mitchell D; Watterson D; Skinner E
    J Clin Epidemiol; 2014 Feb; 67(2):144-51. PubMed ID: 24275500
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Priority setting for health technology adoption at the national level: Lessons learned over 25 years' experience.
    Luxenburg O; Morginstin T; Myers V; Saban M; Shemer J; Wilf-Miron R
    Int J Technol Assess Health Care; 2023 Nov; 39(1):e71. PubMed ID: 37929308
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Toward the Implementation of a Value Framework for Diagnostic Technologies: Operationalization, Piloting, and Validation in Latin America.
    Augustovski F; Argento F; Alcaraz A; García Martí S; Pichon Riviere A; Alfie V
    Value Health; 2024 May; 27(5):570-577. PubMed ID: 38408638
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bioethics, health technology reassessment, and management.
    Soril LJ; Clement FM; Noseworthy TW
    Healthc Manage Forum; 2016 Nov; 29(6):275-278. PubMed ID: 27744278
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An evidence-based framework for identifying technologies of no or low-added value (NLVT).
    Esandi ME; Gutiérrez-Ibarluzea I; Ibargoyen-Roteta N; Godman B
    Int J Technol Assess Health Care; 2020; 36(1):50-57. PubMed ID: 31831086
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Horizon Scanning in Health Care: A German Perspective].
    Krabbe L; Buchberger B
    Gesundheitswesen; 2019 Jul; 81(7):539-543. PubMed ID: 29017192
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Mapping stakeholders' preferences in prioritization criteria for horizon scanning in healthcare technologies].
    Nascimento Ad; Vidal AT; Almeida RT
    Cad Saude Publica; 2016 Aug; 32(7):. PubMed ID: 27487444
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Selecting digital health technologies for validation and piloting by healthcare providers: a decision-making perspective from ontario.
    Chahal A; Rudnick A
    Int J Technol Assess Health Care; 2019 Jan; 35(1):1-4. PubMed ID: 30714547
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adopting new medical technologies in Russian hospitals: what causes inefficiency? (qualitative study).
    Shishkin S; Zasimova L
    Health Econ Policy Law; 2018 Jan; 13(1):33-49. PubMed ID: 28249636
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mapping horizon scanning systems for medical devices: similarities, differences, and lessons learned.
    Ormstad SS; Wild C; Erdös J; Moulton K
    Int J Technol Assess Health Care; 2023 Nov; 39(1):e69. PubMed ID: 37933611
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Health technology reassessment: the art of the possible.
    MacKean G; Noseworthy T; Elshaug AG; Leggett L; Littlejohns P; Berezanski J; Clement F
    Int J Technol Assess Health Care; 2013 Oct; 29(4):418-23. PubMed ID: 24290335
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Achieving optimal technology use: A proposed model for health technology reassessment.
    Soril LJ; MacKean G; Noseworthy TW; Leggett LE; Clement FM
    SAGE Open Med; 2017; 5():2050312117704861. PubMed ID: 28491310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.